Infinimmune announced a research collaboration agreement with Immunome (IMNM) for the discovery and optimization of novel antibodies. Under the agreement, Immunome will receive target exclusivity. Financial terms of the deal were not disclosed. Infinimmune rapidly optimizes and engineers early leads into high-fidelity, development-ready therapeutic candidates using its Glimpse and Anthrobody platforms.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNM:
- Immunome initiated with a Buy at Craig-Hallum ahead of near-term catalysts
- Immunome initiated with a Buy at Craig-Hallum
- Immunome’s Varegacestat: Promising Phase 3 Prospects and Competitive Edge in Desmoid Tumor Treatment
- Gap downgraded, Ulta upgraded: Wall Street’s top analyst calls
- Immunome initiated with an Outperform at Evercore ISI